Bruton's Tyrosine Kinase Inhibition in Multiple Sclerosis.

ABSTRACT:

Purpose of review

Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) with a chronic and often progressive disease course. The current disease-modifying treatments (DMTs) limit disease progression primarily by dampening immune cell activity in the peripheral blood or hindering their migration from the periphery into the CNS. New therapies are needed to target CNS immunopathology, which is a key driver of disability progression in MS. This article reviews Bruton's Tyrosine Kinase Inhibitors (BTKIs), a new class of experimental therapy that is being intensely evaluated in MS. We focus on the potential peripheral and central mechanisms of action of BTKIs and their use in recent clinical trials in MS.

Recent findings

There is evidence that some

SUBMITTER: Schneider R 

PROVIDER: S-EPMC9607648 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature